logo
Here's Why OptimizeRx Corp. (OPRX) is a Great Momentum Stock to Buy

Here's Why OptimizeRx Corp. (OPRX) is a Great Momentum Stock to Buy

Yahoo20 hours ago

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at OptimizeRx Corp. (OPRX), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. OptimizeRx Corp. Currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
In order to see if OPRX is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For OPRX, shares are up 4.21% over the past week while the Zacks Computer - Software industry is up 1.28% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 43.09% compares favorably with the industry's 1.82% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of OptimizeRx Corp. Have risen 98.32%, and are up 25.6% in the last year. In comparison, the S&P 500 has only moved 1.99% and 12.34%, respectively.
Investors should also pay attention to OPRX's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. OPRX is currently averaging 396,163 shares for the last 20 days.
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with OPRX.
Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost OPRX's consensus estimate, increasing from $0.40 to $0.51 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period.
Taking into account all of these elements, it should come as no surprise that OPRX is a #1 (Strong Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep OptimizeRx Corp. On your short list.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OptimizeRx Corp. (OPRX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

Yahoo

time4 hours ago

  • Yahoo

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden's Astra AB and UK's Zeneca Group plc. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include CVRM (cardiovascular, renal and metabolism), Respiratory & Immunology (R&I), Oncology, Rare Diseases, Vaccines and Other. AZN sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 9.3% and 6.7% year-over-year, respectively. Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0 to $4.49 per share. AZN also boasts an average earnings surprise of 4.2%. On a historic basis, Astrazeneca has generated cash flow growth of 18.6%, and is expected to report cash flow expansion of 16.7% this year. Investors should take the time to consider AZN for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lemonade (LMND) Reports Q1 Earnings: What Key Metrics Have to Say
Lemonade (LMND) Reports Q1 Earnings: What Key Metrics Have to Say

Yahoo

time12 hours ago

  • Yahoo

Lemonade (LMND) Reports Q1 Earnings: What Key Metrics Have to Say

Lemonade (LMND) reported $151.2 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 27%. EPS of -$0.86 for the same period compares to -$0.67 a year ago. The reported revenue represents a surprise of +5.05% over the Zacks Consensus Estimate of $143.93 million. With the consensus EPS estimate being -$0.94, the EPS surprise was +8.51%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Lemonade performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: In force premium (end of period): $1.01 billion compared to the $999.35 million average estimate based on four analysts. Premium per Customer (end of period): $396 versus $394.15 estimated by four analysts on average. Customers (end of period): 2,545,496 versus the four-analyst average estimate of 2,535,658. Net loss ratio: 82% versus the four-analyst average estimate of 89%. Gross loss ratio: 78% compared to the 80.8% average estimate based on four analysts. Net investment income: $9.50 million versus the four-analyst average estimate of $8.45 million. The reported number represents a year-over-year change of +25%. Ceding commission income: $26.90 million versus $22.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +28.1% change. Commission income: $10.50 million versus the four-analyst average estimate of $8.02 million. The reported number represents a year-over-year change of +72.1%. Net earned premium: $104.30 million compared to the $105.18 million average estimate based on four analysts. The reported number represents a change of +23.6% year over year. View all Key Company Metrics for Lemonade here>>>Shares of Lemonade have returned +6.7% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lemonade, Inc. (LMND) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

New Strong Buy Stocks for June 5th
New Strong Buy Stocks for June 5th

Yahoo

time14 hours ago

  • Yahoo

New Strong Buy Stocks for June 5th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Pegasystems PEGA: This company which is a leading provider of Customer Relationship Management software that enables transaction-intensive organizations to manage a broad array of customer interactions, has seen the Zacks Consensus Estimate for its current year earnings increasing 8.4% over the last 60 days. Pegasystems Inc. price-consensus-chart | Pegasystems Inc. Quote Telenor TELNY: This company which is a leading telecommunications company in Norway, and among the most advanced telecommunications markets in the world, has seen the Zacks Consensus Estimate for its current year earnings increasing 3.8% over the last 60 days. Telenor ASA price-consensus-chart | Telenor ASA Quote GDEV Inc. GDEV: This gaming and entertainment powerhouse which is focused on growing and enhancing its portfolio of studios, has seen the Zacks Consensus Estimate for its current year earnings increasing 32.1% over the last 60 days. GDEV Inc. price-consensus-chart | GDEV Inc. Quote OP Bancorp OPBK: This banking company which provides commercial banking services to retail and institutional customers, has seen the Zacks Consensus Estimate for its current year earnings increasing 15.1% over the last 60 days. OP Bancorp price-consensus-chart | OP Bancorp Quote Deutsche Bank DB: This largest bank in Germany which offers a wide variety of investment, financial and related products and services, has seen the Zacks Consensus Estimate for its current year earnings increasing 4.2% over the last 60 day. Deutsche Bank Aktiengesellschaft price-consensus-chart | Deutsche Bank Aktiengesellschaft Quote You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report Pegasystems Inc. (PEGA) : Free Stock Analysis Report Telenor ASA (TELNY) : Free Stock Analysis Report OP Bancorp (OPBK) : Free Stock Analysis Report GDEV Inc. (GDEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store